A carregar...
Histone Deacetylase Inhibitors Interrupt HSP90•RASGRP1 and HSP90•CRAF Interactions to Upregulate BIM and Circumvent Drug Resistance in Lymphoma Cells
Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here we show that trichostatin A, romidepsin, and panobino...
Na minha lista:
| Publicado no: | Leukemia |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5474223/ https://ncbi.nlm.nih.gov/pubmed/27890930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.357 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|